Is There Any Switching Costs With a CGM Monitoring Tool?

Dexcom has compounded revenue at 30 plus percent over the past 10 years. Today, we're at penetration a little bit over 50%. There's still some room for growth in the Type 1 side of the market. The real chunky, huge potential growth out there is what if CGM becomes standard of care for Type 2 diabetics? I mentioned that that Center for Medicaid and Medicare services rule change that would potentially increase the addressable market by almost double.

Play episode from 14:48

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app